Developed BCR technology for Alzheimer's biomarkers; passed third-party validation with Linkou Chang Gung Memorial Hospital.
Achieved performance parity with leading brands; liquid version launched; lyophilized version maintains 6-month stability.
Completed pre-clinical testing and authored TFDA EUA submission files.
Achieved A260/A230 > 1.8 with a streamlined 45-minute extraction protocol.
Defined clinical specifications for Alzheimer's biomarkers in hospital diagnostics.
Developed a high-volume (4-6 mL) automated blood gDNA extraction kit with yield and purity matching leading brands.
Provided technical guidance for molecular diagnostics and optimized SARS-CoV-2 platforms to reduce turnaround time.
Investigated the impact of Rlm1p polyglutamine repeats on virulence and drug resistance.
First author in Journal of Agriculture and Forestry, National Chiayi; improved nutritional value and flavor through strain improvement.
First author in TTQAS Annual Conference.
First author in the 23rd Bacteriology Seminar.